Cargando…

Clinical potential of midostaurin in advanced systemic mastocytosis

Advanced (Ad) systemic mastocytoses (SM) include aggressive SM (ASM) and mast cell leukemia (MCL) with or without an associated clonal hematological non-mast cell lineage disease (AHNMD). They are rare (<15%) but are associated with a poor prognosis due to rapid organ dysfunction. To date, respon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chandesris, Marie Olivia, Damaj, Gandhi, Lortholary, Olivier, Hermine, Olivier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467340/ https://www.ncbi.nlm.nih.gov/pubmed/31360083 http://dx.doi.org/10.2147/BLCTT.S87186

Ejemplares similares

A French National Survey on Clotting Disorders in Mastocytosis
por: Carvalhosa, Ana B., et al.
Publicado: (2015)

FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis
por: Kasamon, Yvette L., et al.
Publicado: (2018)

Treatment of Advanced Systemic Mastocytosis with Midostaurin: Practical Guidance for Optimal Therapy and Management
por: Papayannidis, Cristina, et al.
Publicado: (2022)

Real-World Efficacy of Midostaurin in Aggressive Systemic Mastocytosis
por: Szudy-Szczyrek, Aneta, et al.
Publicado: (2021)

Depression in Patients with Mastocytosis: Prevalence, Features and Effects of Masitinib Therapy
por: Moura, Daniela Silva, et al.
Publicado: (2011)

ASXL1 but Not TET2 Mutations Adversely Impact Overall Survival of Patients Suffering Systemic Mastocytosis with Associated Clonal Hematologic Non-Mast-Cell Diseases
por: Damaj, Gandhi, et al.
Publicado: (2014)

Mastocytosis among elderly patients: A multicenter retrospective French study on 53 patients
por: Rouet, Audrey, et al.
Publicado: (2016)

Mast cell sarcoma: new cases and literature review
por: Monnier, Jilliana, et al.
Publicado: (2016)

P1036: REAL-WORLD EFFICACY AND SAFETY OF MIDOSTAURIN-TREATMENT IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS
por: Lübke, Johannes, et al.
Publicado: (2023)

A case of aggressive systemic mastocytosis with bulky lymphadenopathy showing response to midostaurin
por: Sciumè, Mariarita, et al.
Publicado: (2020)

P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE
por: Reiter, A., et al.
Publicado: (2022)

Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy
por: Weisberg, Ellen, et al.
Publicado: (2017)

PB2044: TRIAL IN PROGRESS: OBSERVATIONAL STUDY IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED IN ITALY WITH MIDOSTAURIN (OVIDIO)
por: Grifoni, F. I., et al.
Publicado: (2022)

European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis
por: Tzogani, Kyriaki, et al.
Publicado: (2019)

Neuroimaging evidence of brain abnormalities in mastocytosis
por: Boddaert, N, et al.
Publicado: (2017)

Recent advances in the understanding and therapeutic management of mastocytosis
por: Rossignol, Julien, et al.
Publicado: (2019)

Systemic Mastocytosis Treatment with Midostaurin: [(18)F]FDG PET/CT as a Potential Monitoring Tool for Therapy Outcome
por: Burgard, Caroline, et al.
Publicado: (2022)

Evidence for Cognitive Impairment in Mastocytosis: Prevalence, Features and Correlations to Depression
por: Moura, Daniela Silva, et al.
Publicado: (2012)

Discordant Response of Systemic Mastocytosis Associated With Myelodysplastic Syndrome After Midostaurin and Allogeneic Hematopoietic Stem-cell Transplantation
por: Haas, Marion, et al.
Publicado: (2020)

Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis
por: Lübke, Johannes, et al.
Publicado: (2019)

Mast Cell Leukaemia: c-KIT Mutations Are Not Always Positive
por: Joris, Magalie, et al.
Publicado: (2012)

Targeted Treatment Options in Mastocytosis
por: Vaes, Mélanie, et al.
Publicado: (2017)

Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts
por: Valent, Peter, et al.
Publicado: (2023)

Treatment of Indolent and Advanced Systemic Mastocytosis
por: Buonomo, Alessandro, et al.
Publicado: (2022)

Novel approaches to treating advanced systemic mastocytosis
por: Gilreath, JA, et al.
Publicado: (2019)

Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis
por: Reiter, Andreas, et al.
Publicado: (2022)

Phenotypic and Genotypic Characteristics of Mastocytosis According to the Age of Onset
por: Lanternier, Fanny, et al.
Publicado: (2008)

Recent advances in diagnosis and therapy in systemic mastocytosis
por: Lee, Hyun Jung
Publicado: (2023)

Case-Control Cohort Study of Patients' Perceptions of Disability in Mastocytosis
por: Hermine, Olivier, et al.
Publicado: (2008)

Midostaurin: an emerging treatment for acute myeloid leukemia patients
por: Gallogly, Molly Megan, et al.
Publicado: (2016)

Precision Medicine in Systemic Mastocytosis
por: Nicolosi, Maura, et al.
Publicado: (2021)

Preclinical human models and emerging therapeutics for advanced systemic mastocytosis
por: Arock, Michel, et al.
Publicado: (2018)

Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors
por: Shomali, William, et al.
Publicado: (2021)

Systemic Mastocytosis: Multidisciplinary Approach
por: Zanotti, Roberta, et al.
Publicado: (2021)

Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression
por: Verstovsek, Srdan
Publicado: (2013)

The Effectiveness and Safety of Pharmaceutical-Grade Cannabidiol in the Treatment of Mastocytosis-Associated Pain: A Pilot Study
por: Rossignol, Julien, et al.
Publicado: (2023)

New Insights into the Pathogenesis of Systemic Mastocytosis
por: Li, Zhixiong
Publicado: (2021)

Target Therapies for Systemic Mastocytosis: An Update
por: Sciumè, Mariarita, et al.
Publicado: (2022)

Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and Therapy
por: Martelli, Margherita, et al.
Publicado: (2020)

Midostaurin potentiates rituximab antitumor activity in Burkitt’s lymphoma by inducing apoptosis
por: Ge, Xiaowen, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_omt2pcv7g6hg6aosb5ncm55hje